2. Cell Cycle/DNA Damage Apoptosis
  3. CDK Apoptosis
  4. SR-4835

SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death.

For research use only. We do not sell to patients.

CAS No. : 2387704-62-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 17 publication(s) in Google Scholar

SR-4835 Related Antibodies

Top Publications Citing Use of Products

    SR-4835 purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2025 Jun;26(11):2836-2854.  [Abstract]

    Inhibitory profile of S656, CR8, SR4835, HQ461, NCT02, THZ531 and SNS-032 compounds across 40 primary AML specimens in dose response assays. IC50 values were determined after 6 days of incubation and normalized to DMSO control.

    SR-4835 purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2023 May 5;25(1):51.  [Abstract]

    Proliferative response upon treatment with dose range of lapatinib in combination with transcriptional CDK inhibitor SR4835 (0.01 and 0.0316 µM) in Hs578T.

    SR-4835 purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2023 May 5;25(1):51.  [Abstract]

    Proliferative responses of dose ranges of transcriptional CDK inhibitors THZ531, THZ1, CDKI-73, PHA-767491, SR4835 and flavopiridol, alone, or in combination with KO143 (1 µM) or lapatinib (1 µM).

    SR-4835 purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2024 Jan;300(1):105501.  [Abstract]

    dose-response curves for the inhibition of Cdk12/CycK and Cdk13/CycK by SR-4835. Radioactive kinase activity assays were performed for a concentration series of SR-4835 in presence of 0.2 μM indicated kinase and 0.2 mM [32P]-γ-ATP. Assays were started by addition of 100 μM pS7-CTD[3] substrate and incubated for 60 min. Measurements were performed in triplicates.

    SR-4835 purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2024 Jan;300(1):105501.  [Abstract]

    SR-4835 was tested at 0, 0.1, 1, 10, and 100 μM concentration against various CMGC kinases.

    View All CDK Isoform Specific Products:

    View All Isoforms
    CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death[1].

    IC50 & Target[1]

    CDK12

    99 nM (IC50)

    CDK12

    98 nM (Kd)

    CDK13

    4.9 nM (Kd)

    In Vitro

    SR-4835 (90 nM; 0.5-48 hours) suppresses ATM and RAD51 protein levels[1].
    ? SR-4835 inhibits CDK12/CDK13 which triggers intronic polyadenylation site cleavage and suppresses the expression of core DNA damage response proteins[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    SR-4835 Related Antibodies

    Western Blot Analysis[1]

    Cell Line: MDA-MB-231 cells
    Concentration: 90 nM
    Incubation Time: 0.5, 6, 24, 48 hours
    Result: Suppressed ATM and RAD51 protein levels.
    Molecular Weight

    499.36

    Formula

    C21H20Cl2N10O
    CAS No.
    Appearance

    Solid

    Color

    Off-white to light brown

    SMILES

    CN1N=CC(N2C3=NC(N4CCOCC4)=NC(NCC5=NC6=C(N5)C=C(Cl)C(Cl)=C6)=C3N=C2)=C1
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 25 mg/mL (50.06 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.0026 mL 10.0128 mL 20.0256 mL
    5 mM 0.4005 mL 2.0026 mL 4.0051 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2 mg/mL (4.01 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 0.89 mg/mL (1.78 mM); Clear solution

      This protocol yields a clear solution of ≥ 0.89 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.9 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  20% HP-β-CD in Saline

      Solubility: 5 mg/mL (10.01 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.73%

    SDS (393 KB)

    COA (252 KB) HNMR (272 KB) LCMS (267 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.0026 mL 10.0128 mL 20.0256 mL 50.0641 mL
    5 mM 0.4005 mL 2.0026 mL 4.0051 mL 10.0128 mL
    10 mM 0.2003 mL 1.0013 mL 2.0026 mL 5.0064 mL
    15 mM 0.1335 mL 0.6675 mL 1.3350 mL 3.3376 mL
    20 mM 0.1001 mL 0.5006 mL 1.0013 mL 2.5032 mL
    25 mM 0.0801 mL 0.4005 mL 0.8010 mL 2.0026 mL
    30 mM 0.0668 mL 0.3338 mL 0.6675 mL 1.6688 mL
    40 mM 0.0501 mL 0.2503 mL 0.5006 mL 1.2516 mL
    50 mM 0.0401 mL 0.2003 mL 0.4005 mL 1.0013 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    SR-4835 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    SR-48352387704-62-1SR4835SR 4835CDKApoptosisCyclin dependent kinaseInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    SR-4835
    Cat. No.:
    HY-130250
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.